Advocacy and Outreach by NPA Leadership
- NPA letter of thanks to FDA re e-cigarette regulation (May 2016)
- Dr. Andrew Kolodny’s testimony before Congress: Opioids and the FDA” (February 2016)
- Health Affairs Blog, “The 21st Century Cures Act: More Homework To Do” (September 2015)
- Article by John H. Powers III, MD in Annals of Internal Medicine, “Regulating Antibiotics in an Era of Resistance: The Historical Basis and Continued Need for Adequate and Well-Controlled Investigations” (July 2015)
- HealthNewsReview.org post, “Criticism of NEJM’s defense of industry-physician relations” (May 2015)
- Dr. Richard Bruno’s FDA Testimony: Antibiotic Ceftazadime-Avibactam (CAZ-AVI) (December 2014)
- Testimony Before AIDAC by John Fratti, Dr. Susan Molchan, Joseph Brodine, and Reshma Ramachandran (December 2014)
- Testimony before the FDA Anti-Infective Drugs Advisory Committee by Dr. Nida Degesys (March 2014)
- Washington Post Letter to the Editor, “Focus on the roots of antibiotic resistance, not the hype,” by Dr. Lisa Plymate (October 2013)
- Testimony before FDA Advisory Board by Dr. Lisa Plymate (October 2013)
- Brookings Institute Presentation by Dr. Cheryl Bettigole (August 2013)
- Testimony on Calcitonin given by NPA board member Dr. Mary Carol Jennings on behalf of the NRCW (March 2013)
- Testimony on Gabapentin given by NPA board member Dr. Mary Carol Jennings on behalf of the NRCW (March 2013)
- Testimony on Paroxetine given by NPA board member Dr. Mary Carol Jennings on behalf of the NRCW (March 2013)